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Ovarian cancer is the seventh most common cancer in women
worldwide, with 239 000 new cases diagnosed in 2012.1Aswith
many other types of cancer, geographical variation in the
incidence of and mortality from ovarian cancer is substantial,
with a higher incidence in economically developed regions of
the world.2 Incidence is highest in the 50-70 year old age group,
with 75% of cases diagnosed in women aged more than 55
years.3 In 80% of women the disease will be advanced at
presentation, with a low five year survival rate; the all stage five
year survival in the United Kingdom is 46%.4 This low survival
rate in the UK has been recognised in the International Cancer
Benchmarking Partnership and has been attributed at least partly
to less timely diagnosis.5 This review summarises the presenting
features, diagnostic tests, risk factors, and groups at high risk
of ovarian cancer and is aimed at primary care practitioners and
hospital doctors in other specialties.
What are the types of ovarian cancer and
why is this relevant?
Ovarian cancer refers to a diverse set of histological types of
cancers. Most ovarian cancers are epithelial in origin, with high
grade serous carcinomas accounting for 70-80% of cases and
the rarer types, including clear cell (3%), endometrioid (<5%),
and mucinous (<3%) cancer.6 Non-epithelial histology types
include the rarer germ cell tumours and stromal tumours.
Differences in histology correlate with differences in molecular
characteristics and clinical behaviour. Currently, on the basis
of clinical or molecular and histological patterns, ovarian cancer
can be divided into two types—type 1, which comprises clear
cell, mucinous, endometrioid, and low grade serous cancer
histology, and type 2, which comprises high grade serous
cancers. Type 1 cancers tend to be slow growing, indolent, and
more likely to be detected earlier by ultrasonography, whereas
type 2 cancers are typically fast growing and spread early.
Paradoxically, type 1 cancers can be more challenging to treat,
as these tumour types are less chemosensitive.
One important development in recent years is the recognition
that the primary source of previously termed “ovarian” cancer
is in fact the distal end of the fallopian tube, and seemingly the
main site of origin for many high grade serous cancers. This
has implications for both screening and preventive strategies.7
What risk factors are associated with
ovarian cancer?
Epidemiological risk factors
Epidemiological studies show that the number of ovulatory
cycles a woman has in her lifetime is proportional to her risk
of developing ovarian cancer, with reduced numbers of
ovulatory cycles such as from pregnancy or the use of the
contraceptive pill being associated with a protective effect.
Conversely, nulliparity, a history of breast cancer, and a familial
history of breast and ovarian cancer are recognised risk factors,
with recent reports suggesting a small increased risk with
hormone replacement therapy.8 Ovarian cancer is also much
more common in the postmenopausal age group.3
Genetic risk factors
Large cohort studies show that in approximately 20% of women
an inherited genetic mutation confers a higher risk of developing
ovarian cancer.9 By age 70 the lifetime risk of ovarian cancer
and breast cancer in womenwith a BRCA1mutation is as much
as 63% and 85%, respectively, and in women with a BRCA2
mutation it is as much as 27% and 84%, respectively.10Therefore
women with a strong family history of breast and ovarian cancer
or a known history of a BRCA mutation should be considered
at higher risk of ovarian cancer.
The Jewish community, particularly the Ashkenazi population,
has a high rate of BRCA mutations and should be considered
at increased risk for the development of both breast and ovarian
cancer. Two large prospective studies testing Jewish
communities in Israel and London, irrespective of family history,
for three founder mutations in the BRCA genes showed that
one in three womenwith BRCAmutations did not have a family
history of cancer.11 12 Large case-control series showed that
women with BRCA mutations tend to have tumours that are
sensitive to platinum and have visceral metastases, with 10 year
survival that is similar to cohorts without the BRCAmutations.
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The bottom line
• NICE recommends symptom triggered testing using sequential CA125 and ultrasonography for ovarian cancer
• Ovarian cancer is most common in the postmenopausal age group
• CA125 is not a specific marker in premenopausal women and may be increased during menstruation and in other conditions
• Ovarian cysts are common in premenopausal women and may be physiological
• Ultrasound findings of simple or unilocular cysts (that is, fluid-containing cysts) measuring <5 cm on ultrasonography are reassuring
and associated with less than a 1% risk of malignancy
• All women with a diagnosis of high grade serous ovarian cancer may be offered routine testing for BRCA. Women with known BRCA
mutations may be offered risk reducing surgery to remove the fallopian tubes and ovaries
Sources and selection criteria
We carried out an electronic search of PubMed, Medline, Embase, the Cochrane Library, and the Cochrane database of systematic reviews
using the search term “ovarian cancer.” Only those papers that were written in English, were published within the past 10 years, and described
studies with adequate scientific validity were considered. We also referred to personal archives of papers from 2009 to 2015 and guidance
documents from the National Institute for Health and Care Excellence (CG122 and NG12). A comprehensive evidence review was performed
during 2009-10 by the National Collaborating Centre for Cancer, on which NICE clinical guidance CG122 is based.
Combined 10 year overall survival rates were 30% for
non-carriers of BRCAmutations, 25% for BRCA1 carriers, and
35% (95% confidence interval 30% to 41%) for BRCA2
carriers.13
How do women with ovarian cancer
present?
Recent retrospective case-control studies found that women
generally have several persistent or frequently occurring
non-specific symptoms including abdominal distension or
“bloating,” a feeling of fullness or loss of appetite, pelvic or
abdominal pain, increased urinary urgency or frequency,
unexplained weight loss, fatigue, or changes in bowel habit.14 15
These symptoms are common; interrogation of general practice
databases suggests that on average one in two women between
the ages of 45 and 70 consult their general practitioner each
year with these symptoms.16-18 This presents a diagnostic
dilemma for doctors, given the low incidence of ovarian cancer
(an average UK general practitioner sees one woman with
ovarian cancer once every 3-5 years), the low positive predictive
value of symptoms,15 19 and the lack of clear diagnostic
pathways. A large survey of UK patients’ experiences found
that 36% of women with a subsequent diagnosis of ovarian
cancer, present to their general practitioner with symptoms three
or more times before diagnosis.20 In the UK the mean time from
first symptoms to first presentation is 39 days and the mean
time from first presentation to diagnosis is 21 days.21 Indeed,
ovarian cancer is one of several cancers classified as “harder to
suspect.”22Analysis of routes to diagnosis in routinely collected
national datasets shows that almost one third of women with
ovarian cancer in the UK receive a diagnosis through emergency
departments and a further third through cross specialty
referrals.23 Women presenting at emergency departments often
have ascites, pleural effusions, bowel obstruction, and low
albumin levels impacting adversely on treatment choices and
survival. Women presenting as emergencies have a worse
survival than those diagnosed electively through rapid access
clinics.23 24
When should ovarian cancer be suspected
in primary care?
Guidance from the National Institute for Health and Care
Excellence in the UK and the US basedNational Comprehensive
Cancer Network recommend symptom triggered testing for
ovarian cancer.25 26Women with persistent symptoms of
abdominal distension or “bloating,” early satiety, loss of
appetite, pelvic or abdominal pain, increased urinary urgency
or frequency, unexplained weight loss, fatigue, or changes in
bowel habit should be tested in the primary care setting and
referred urgently to secondary care, with the aim of achieving
faster diagnosis and treatment, and thereby improved survival.
NICE recommends sequential testing of serumCA125 followed
by abdominopelvic ultrasonography if the serum CA125 level
is 35 IU/L or more.Women with clinical findings of ascites and
a pelvic or abdominal mass should be referred urgently (figure⇓).
These recommendations were based on evidence from
case-control studies, but since then two large well conducted
prospective studies with over 6500 women have been published
showing that symptom triggered diagnostic testing of CA125
level and ultrasonography for ovarian cancer does not result in
a stage shift in ovarian cancer but may result in more patients
undergoing complete removal of tumour at surgery suggesting
lesser tumour load in women detected through symptom
triggered testing. 27 28 At present the impact on mortality with a
strategy of symptom triggered diagnostic testing is not known.
The implementation of symptom triggered testing is challenging
in clinical practice. A survey of general practitioners found that
most would refer patients on the basis of increased CA125 levels
even if the ultrasonography finding was normal.29A recent audit
of outcomes in two week wait clinics in pre-guideline and
post-guideline cohorts showed that current implementation has
led to an increase in the predictive value of detecting cancer
through rapid access clinics but no impact on stage at
presentation.30 This audit also reported that for most referrals
guidance for sequential testing for suspected ovarian cancer was
not followed (90%), most had heterogeneous symptoms, and
most were made on the basis of what the doctor considered
either increased CA125 levels or abnormal ultrasonography
findings. Furthermore, most women referred (66%) were
premenopausal, where the risk of ovarian cancer is low.30NICE
did not issue any age limits in guidance; however, it was
emphasised that the high risk group was women aged more than
50 years.
Are CA125 tests and ultrasonography
reliable?
CA125 testing
CA125 is a non-specific marker, the levels of which can be
increased in several conditions, many associated with benign
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conditions—for example, endometriosis andmenstruation. This
needs to be remembered whenwomen are counselled (see box),
as should the fact that the development of an ovarian cyst is a
physiological prerequisite to ovulation. A further complicating
factor is that the level of CA125 is only increased in 50% of
stage 1 cancers.
Ultrasonography
Currently there is no universally agreed scoring system to triage
women with suspected benign or malignant adnexal masses
detected by ultrasonography at primary care level. This can
create a difficulty for general practitioners in interpreting reports
from the US, particularly as NICE guidance does not contain
recommendations onwhat constitutes abnormal ultrasonography
findings. Ovarian masses that are multilocular, bilateral, solid,
or associated with ascites and metastasis are extremely
suspicious and should prompt rapid referral. Data from the UK
Collaborative Trial of Ovarian Cancer Screening in primary
care and other large prospective studies in secondary care show
that findings of simple or unilocular cysts (that is,
fluid-containing cysts), measuring <5 cm on ultrasonography
are reassuring and associated with a less than 1% risk of
malignancy.31 32 Large prospective studies from the International
Ovarian Tumour Analysis consortium suggest that utilising “m”
(malignant) and “b” (benign) rules to identify masses as
suspicious may be highly accurate. Using these rules, the
reported sensitivity was 95%, specificity 91%, positive
likelihood ratio 10.37, and negative likelihood ratio 0.06.33 The
accuracy of these rules has been demonstrated in secondary
care, predominantly with specialists in ultrasonography.
Translating this to a primary care setting may have a positive
impact but is possibly challenging to achieve owing to variation
in ultrasound services and providers and in achieving quality
assurance.
How can ovarian cancer be detected in
premenopausal women?
One important group of women should be highlighted, although
their situation is rare. Germ cell tumours must be suspected in
women aged less than 25 with a pelvic mass and these women
should be referred urgently to hospital as conservative surgery
followed by chemotherapy can be lifesaving. Increased levels
of tumour markers β human chorionic gonadotrophin, alpha
fetoprotein, and lactate dehydrogenase can aid diagnosis in this
subset and should be requested but should not delay referral.
By the age of 65 years, 4% of women will have been admitted
to hospital with an ovarian cyst, making this the fourth most
common gynaecological reason for hospital admission in
England.4 In the UK each year about 1000 women aged less
than 50 will receive a diagnosis of ovarian cancer. Among
premenopausal women, more than 90% of surgically managed
cases are benign, compared with just 60% in the postmenopausal
population.
The present recommendation for referral by a general
practitioner is based on symptoms and the results of the CA125
test, although optimal diagnostic pathways for premenopausal
women with a complex ovarian mass and increased CA125
levels are not defined. Greatly increased levels of CA125 (>200
units/mL) or rapidly increasing levels should be considered
more suspicious in this group.34 Women may be reassured to
know that the CA125 test can be abnormal as a result of
menstruation, and that ovarian cysts can be physiological.
Research focusing on women who are referred with symptoms
and increased CA125 levels or abnormal adnexal masses, aims
to enhance the ability to triage women appropriately. The
ROCKETS project (www.birmingham.ac.uk/ROCKETS) has
been funded by the National Institute for Health Research to
identify, derive, and validate improved tests and risk scores for
premenopausal and postmenopausal women in both primary
and secondary care. This project is under way and should
provide useful information on optimal diagnostic pathways in
the future.
What is the role of screening and
prevention strategies?
One large randomised US based trial compared annual screening
using CA125 testing and ultrasonography, with volunteers in
the control arm not undergoing any investigations. This trial
did not find a stage shift or mortality benefit from this screening
strategy in ovarian cancer. However, the largest randomised
controlled trial, the UK Collaborative Trial of Ovarian Cancer
Screening (200 000 women), which evaluates a different
screening strategy using a ROCA (risk of ovarian cancer
algorithm) constructed on serial CA125 levels is due to report
later this year, and the results are awaited with interest. The
most recent results from the trial show that serial testing with
the ROCA algorithm doubles the number of ovarian cancers
detected compared with testing using single thresholds of
CA125.35
Given the recent understanding that the fimbrial end of the
fallopian tube is the starting site of neoplastic transformation
for many women, population based opportunistic postpartum
salpingectomy is now being evaluated in British Columbia,
Canada, as a prevention strategy for epithelial ovarian cancer.36
Long term incidence andmortality data are expected in 10 years.
What is recommended for women with a
known genetic predisposition?
Risk reducing salpingo-oophorectomy has been widely adopted
as a key component of breast and gynaecological cancer risk
reduction for women with BRCA1 and BRCA2mutations once
they have completed their families.37Alternative strategies such
as delayed salpingectomy to spare the menopause have been
proposed. The large UK Familial Ovarian Cancer Screening
study in BRCA mutation carriers shows that surveillance with
four monthly CA125 testing and ultrasonography does not
reduce mortality from ovarian cancer.38
Are there any tests on the horizon?
Better “tests” to discriminate between malignant and benign
ovarian masses would be most welcome, as this would reduce
unnecessary testing, hospital visits, and, importantly, the distress
associated with a diagnosis of possible malignancy when that
may not be the case. Newer biomarkers such as HE4 or OVA1
both singly or in conjunction with CA125 may improve the
detection of ovarian cancer; neither has been tested in the
primary care population yet. Novel testing using sophisticated
genomic technology shows considerable promise in the early
detection of ovarian cancer. Plasma circulating tumour DNA
can identify small tumour loads. A recent study in a small series
of 40 women showed that it was possible to identify accurately
cells shed by ovarian tumours into cervical smears.39 40 Both
tests are worthy of future investigation.
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What to tell women undergoing a CA125 test
• This blood test measures a protein called CA125 in your blood
• The level of CA125 can be increased in several conditions, including endometriosis, menstruation, ovarian cysts, diverticulitis, and
sometimes ovarian cancer. So having increased levels of CA125 does not necessarily mean you have ovarian cancer
• If the result shows an increased level, then your doctor will arrange an ultrasound scan of your ovaries
• If the test comes back at a very increased level your doctor will refer you to see a specialist
• A normal level does not rule out ovarian cancer (especially at an early stage), so if your symptoms persist then you will need to see
your doctor again. Keeping a symptoms diary may be helpful before a further consultation
What treatments are available for ovarian
cancer?
The mainstay of treating ovarian cancer is a combination of
surgery and chemotherapy—the latter normally platinum based.
The best outcomes are in women with early stage disease, and
in those with advanced disease, where the entire tumour is
surgically removed and the disease is sensitive to platinum based
chemotherapy. Even in the most favourable group treated for
advanced disease, about 70% will relapse within 18 months.41
In some women with advanced disease, initial chemotherapy
rather than surgery may be deemed the better approach, with
surgery delayed until after three chemotherapy cycles.42
Depending on the timing of relapse of disease, some women
will achieve long remissions, but the reality is that management
at relapse is palliative rather than curative. Treatment at this
stage will be mainly chemotherapy (or other agents), and indeed
surgery may have a role in selected women.
What are the survival statistics?
Ten year survival remains poor, at 35%. Survival from ovarian
cancer is highly stage dependent (five year relative survival
92% stage I v 5% stage IV).43 A shift at stage of presentation or
a reduction in tumour load at stages III/IV ovarian cancer is
likely to substantially improve survival from ovarian cancer
and must be essential aims of future research and change
implementation programmes in the National Health Service.
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A patient’s perspective
I researched my family tree and highlighted every member who has had cancer. It is covered in yellow highlighter pen.
My maternal grandmother died aged just 34. Three of her four children had cancer. I have four cousins under 50 who have had cancer. My
poor family has been devastated by cancer.
In 2007 I had a mammography which detected breast cancer. I had no symptoms, but told the cancer specialists about my cousins. They
said they were not closely related and not to worry. I had a lumpectomy, four lymph glands removed, radiotherapy, and tamoxifen. I took
four days off work.
Three years later one of my cousins died of breast cancer and my general practitioner agreed to a genetic test. I was BRCA2 positive, which
explained my sad family history. I was counselled and once I knew the risks of ovarian cancer I decided to have my ovaries removed. My
daughter was tested and was negative, thank goodness.
My ovaries were removed in 2012. No follow-up was required and I thought I had sorted it. But I started feeling bloated and I had indigestion
and felt tired. I dismissed this as overeating and part of the healing process and my GP agreed. My symptoms worsened and I had a blood
test—which showed my CA125 level to be 3800. My GP then discovered that the histology reports from my ovarian surgery were still
outstanding.
Once recovered, they revealed that at the time of my surgery my tissue had tested positive for grade 1c ovarian cancer. This information
had been lost in the system. By now I had stage 3c high grade serous adenocarcinoma of the fallopian tubes.
I just sat there, completely unable to take in the seriousness of my situation. I left to go home—I live on my own—and looked up ovarian
cancer through Google, which was a bad move.
A scan revealed the cancer had spread to my sternum, pulmonary tissue, and peritoneum. I was told I did not have long to live. I started
chemotherapy and my oncologist said I had a 20% survival rate and an 80% chance of recurrence, with two to three years to live.
Somehow I have come through this.
Telling the medical students about my experience and answering their questions means my story can teach them about diagnosis and
communication and about seeing women like me in the context of our families and our whole lives. They really listened hard.
The students wanted to know if I was angry, but I’m not, not now. They asked me how bad news should be delivered and I said not when
you’re alone like I was. The students also wanted to know more about ongoing side effects from chemotherapy, so we had a good chat
about that.
This project has given me confidence to speak about my cancer, which is very personal and was a terrible trauma. The students really
wanted to hear me.
To know more about “Survivors teaching students”, please contact the charity Ovacome on RuthG@ovacome.org.uk or
www.ovacome.org.uk/
Questions for future research
What are optimal pathways of diagnosis in primary and secondary care in premenopausal and postmenopausal women with non-specific
symptoms (www.birmingham.ac.uk/ROCKETS)?
Can novel technologies (for example, plasma circulating tumour DNA, sequencing of exfoliated tumour DNA in cervical smears, urine
steroid profiles) improve diagnostic testing for ovarian cancer?
What are best surveillance strategies in patients with BRCA mutations who are at high risk for the development of ovarian cancer?
Can multidisciplinary clinics investigating women with non-specific symptoms improve earlier detection of ovarian cancer?
Can general practitioners identify patients for investigation or refer differently to improve earlier detection of ovarian cancer?
Additional educational resources
Resources for healthcare professionals
Target Ovarian Cancer websites
www.targetovariancancer.org.uk/health-professionals/gps/diagnosing-ovarian-cancer—advice for general practitioners about diagnosing
ovarian cancer
www.targetovariancancer.org.uk/health-professionals/gps/get-trained—free online learning tools for general practitioners to help them
diagnose ovarian cancer
Resources for patients
www.targetovariancancer.org.uk, www.ovacome.org.uk, and www.ovarian.org.uk—websites providing women with an up to date guide
on the management options after a diagnosis of ovarian cancer
www.targetovariancancer.org.uk/about-ovarian-cancer/what-ovarian-cancer/ovarian-cancer-symptoms—describes the symptoms of
ovarian cancer and includes a video
www.targetovariancancer.org.uk/sites/default/files/Target-Ovarian-Cancer-symptoms-leaflet.pdf—downloadable leaflet (PDF) discussing
symptoms
www.targetovariancancer.org.uk/about-ovarian-cancer/familial-ovarian-cancer/symptoms-and-risks-factors—discusses familial risk and
includes a link to Macmillan’s online risk assessment tool (OPERA)
www.targetovariancancer.org.uk/sites/default/files/Ovarian%20cancer%20information/10-top-tips-for-patients-seeing-GPs-about-ovarian-
cancer_0.pdf—downloadable leaflet (PDF) with top 10 tips for seeing your general practitioner
www.targetovariancancer.org.uk/sites/default/files/Ovarian%20cancer%20information/CA125-factsheet-for-ovarian-cancer-tests-Target-
Ovarian-Cancer-2015.pdf—downloadable leaflet (PDF) on CA125
www.targetovariancancer.org.uk/sites/default/files/Ovarian%20cancer%20information/Ultrasound-factsheet-for-ovarian-cancer-tests-
Target-Ovarian-Cancer-2015_0.pdf—downloadable leaflet (PDF) on ultrasonography for suspected ovarian cancer
How were patients included in the creation of this article?
A patient who talked to medical students in October 2014 about her experience as part of “Survivors teaching students” has given an account
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Figure
Flow chart for diagnosis of ovarian cancer. Adapted from NICE26
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